Skip to main content

Table 1 Summary of baseline demographics, disease and clinical characteristics of the AGREE study patients (N = 509)

From: Identification of poor prognostic joint locations in an early rheumatoid arthritis cohort at risk of rapidly progressing disease: a post-hoc analysis of the Phase III AGREE study

 

ABA + MTX (N = 256)

MTX (N = 253)

Total (N = 509)

n

Value

n

Value

n

Value

Age in years, mean (SD)

256

50.1 (12.4)

253

49.7 (13.0)

509

49.9 (12.7)

Gender, n (%) female

256

196 (76.6)

253

199 (78.7)

509

395 (77.6)

Race, n (%) White

256

202 (78.9)

253

219 (86.6)

509

421 (82.7)

Disease duration in months, mean (SD)

256

6.2 (7.5)

253

6.7 (7.1)

509

6.5 (7.3)

Tender joints, mean (SD)*

256

31.3 (14.8)

253

30.8 (14.0)

509

31.0 (14.4)

Swollen joints, mean (SD)*

256

22.9 (11.3)

253

21.9 (10.1)

509

22.4 (10.8)

DAS28-CRP, mean (SD)

256

6.3 (1.0)

252

6.2 (1.0)

508

6.3 (1.0)

HAQ DI, mean (SD)

254

1.7 (0.7)

251

1.7 (0.7)

505

1.7 (0.7)

ACPA-positive, n (%)

256

236 (92.2)

253

217 (85.8)

509

453 (89.0)

RF-positive, n (%)

256

246 (96.1)

253

245 (96.8)

509

491 (96.5)

Total x-ray score, mean (SD)

253

7.5 (9.7)

253

6.7 (8.8)

506

7.1 (9.2)

Erosion score, mean (SD)

253

5.4 (6.1)

253

4.8 (5.4)

506

5.1 (5.8)

Joint-space narrowing score, mean (SD)

253

2.1 (4.2)

253

1.9 (4.0)

506

2.0 (4.1)

  1. N, total number of patients; n, number of patients included in each treatment group; SD, standard deviation, ABA, abatacept; MTX, methotrexate; DAS28-CRP, disease activity score in 28 joints-C-reactive protein; HAQ DI, health assessment questionnaire disability index; ACPA, anti-citrullinated protein antibody; RF, rheumatoid factor; Total x-ray score, total Sharp score using the Genant-modified Sharp method
  2. *A total of N = 68 and N = 66 joints were assessed for tender and swollen joints, respectively